BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta (NKTX)NkartaEarnings

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 Cash balance of $295.1 million on December 31, 2025, including

Related news

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-05-12 20:01 EST

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-04-15 20:01 EST

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

NKTXNkarta2026-04-09 11:00 EST

Nkarta to Participate in Needham Virtual Healthcare Conference

NKTXNkarta2026-03-25 20:01 EST

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

NKTXNkarta2026-02-27 13:00 EST

Nkarta to Participate in March Investor Conferences

Stock data

Close
2.29 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States